Noticias

Noticias

  • Título: Lombard Medical, Inc. files registration statement with SEC ahead of proposed IPO on NASDAQ Global Market
  • Fecha: 11-03-2014

  • London, UK and Irvine, CA, 11 March, 2014 – Lombard Medical Technologies PLC (AIM: LMT), the specialist

    medical device company focused on Endovascular Aortic Repair (“EVAR”) of abdominal aortic aneurysms

    (“AAAs”), announced today that Lombard Medical, Inc. has filed a registration statement on Form F-1 with the

    U.S. Securities and Exchange Commission (“SEC”) relating to a proposed initial public offering of its ordinary

    shares. The number of shares to be offered and the price range for the offering have not yet been determined.

    The Company has reserved the ticker “EVAR” for its listing on the NASDAQ Global Market. In connection with

    the NASDAQ listing, Lombard Medical will also delist its ordinary shares from AIM, a market of the London Stock

    Exchange and complete a change of domicile, with Lombard Medical, Inc., a Cayman Islands corporation,

    becoming the holding company for the group.

    Lombard Medical intends to use proceeds from the proposed NASDAQ offering to expand its direct sales force

    in the United States and develop new products to treat complex vascular disease, including a stent graft to treat

    aneurysms in the thoracic aorta. The remaining proceeds will be used for working capital and for general

    corporate purposes.

    Jefferies LLC and Barclays Capital Inc. are acting as joint book-running managers or the proposed offering, and

    BTIG, LLC is acting as co-manager.

    The proposed offering of these securities will be made only by means of a prospectus. When available, copies of

    the preliminary prospectus relating to the offering may be obtained from Jefferies LLC, Equity Syndicate

    Prospectus Department, by email at Prospectus_Department@Jefferies.com, by phone at 877-547-6340 or by

    mail at 520 Madison Avenue, 2nd Floor, New York, NY 10022 or Barclays Capital Inc., c/o Broadridge Financial

    Solutions, by email at Barclaysprospectus@broadridge.com, by phone at 888-603-5847 or by mail at 1155 Long

    Island Avenue, Edgewood, NY 11717.

    A registration statement relating to these securities has been filed with the SEC but has not yet become

    effective. These securities may not be sold nor may offers to buy be accepted prior to the time the

    registration statement becomes effective.

    This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there by any

    sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful

    prior to registration or qualification under the securities laws of any such state or jurisdiction.



  • Fuente: endovascular.es